PhD Scientific Days 2026

Pharmaceutical Sciences and Health Technologies 1.

Anticancer properties of Tyrosine Kinase Inhibitors Against Human Triple-Negative Breast Cancer Cells In vitro

Előadó neve

Abdallah Abdallah Abdallah, Ejlal, PhD

Neptune code

JJYRAU

Előadó munkahelye

Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged

Előadó telefonszáma

06303290254

Előadó e-mail címe

ejlalpharma12@gmail.com

Az előadás címe

Anticancer properties of Tyrosine Kinase Inhibitors Against Human Triple-Negative Breast Cancer Cells In vitro

Szerző(k) neve és munkahelye

Ejlal Abdallah Abdallah1¹

1: 1Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged

Bemutatás módja

Szóbeli

Szekció

Pharmaceutical Sciences and Health Technologies 1.

Language of the presentation

English

Preferred session

Pharmaceutical Sciences and Health Technologies

Összefoglaló szövege

Introduction:
Despite research progress, cancer, particularly triple-negative breast cancer, continues to pose a significant health challenge. Efforts focus on developing effective agents, such as tyrosine kinase inhibitors (TKIs) that target pathways involved in cancer growth. Although first-generation TKIs like imatinib have shown promise, challenges such as resistance and adverse effects persist, driving the pursuit of next-generation TKIs.
Aims:
Based on these reports, our study aimed to characterize the anticancer properties of a recently
Synthesized TKIs (TKI-1, TKI-2, TKI-3) on breast cancer cell lines.
Methods:
The standard MTT method was used to assess the antiproliferative effects of the tested compounds on breast (MDA-MB-231, MCF-7) cancer cells.
The possible mechanism of action in the selected cell lines was assessed by flow cytometry after propidium iodide staining to monitor cell cycle progression, and the antimigratory effect was investigated using a wound-healing assay.
Results:
All tested compounds were promising, achieving over 90% growth inhibition across all cell lines at 10 µM, with calculated IC50 values lower than that of the reference agent, cisplatin, and substantially less effect on NIH/3T3 fibroblasts and h-tert HME1 cells, with calculated IC50s ranging from 0.58 µM to 1.10 µM.
TKIs were found to induce cell cycle disturbances in a concentration-dependent manner (0.5 and 1 μM), characterized by a significant decrease in the proportion of cells in the G0/G1 phase and a substantial accumulation of cells in the S and G2/M phases at 24 h and 48 h. Additionally, a remarkable increase in the SubG1 cell population was observed, particularly at higher concentrations and after longer incubation times, indicating apoptosis induction.
Moreover, TKIs were found to exert a concentration- and time-dependent antimigratory effect at subinhibitory concentrations, with TKI-3 being most effective against MDA-MB-231 cells and TKI-2 most effective against MCF-7 cells.
Conclusion:
Based on our current results, TKI-1, TKI-2 and TKI-3 are potent antiproliferative, and antimigratory molecules that could be serve as a model for developing new treatments against breast cancer.
Funding:
"Supported by Hungarian Research Foundation (NKFI), grant number K143690."
"The Stipendium Hungaricum Scholarship Program, coordinated by the Tempus Public Foundation"

University

University of Szeged

Supervisor

Prof. Dr. István Zupkó and Dr. Noémi Bózsity-Faragó

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies after complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

jóváhagyta

Előadó

9711

Start

15:45

End

15:55